ClearPoint Neuro heads into tomorrow's earnings report carrying one of the most charged short-selling setups in the health care equipment space.
Short sellers are deeply committed here — and haven't flinched despite a punishing month for the bears. Short interest runs at 16.2% of the free float, a level that ranks in just the 2nd percentile of ORTEX's universe, meaning almost every comparable stock is less shorted. That figure edged down roughly 0.7% over the past week, but the broader monthly trend tells the opposite story: shorts added about 7.7% more exposure over the last 30 days. Against that backdrop, the stock has surged 42% in the past month to $12.31, closing down 4% on Monday after the prior week's 10% advance. That price action has pushed the ORTEX short score to 75.5 — a level that flags sustained, organised short pressure rather than casual positioning. Borrow availability remains easy, with cost to borrow under 1% and lending-pool availability not under material pressure, which means shorts face no mechanical squeeze forcing them to cover.
The bull-bear divide is straightforward: revenue growth versus path to profitability. Bulls point to the biologics partnership pipeline, where ClearPoint's platform is increasingly embedded as a drug-delivery infrastructure layer — a model that, if it scales, transforms unit economics without proportional cost growth. B. Riley, the most active covering analyst, raised its target to $20 in March after the last print, maintaining its Buy rating. The mean analyst target of $22 sits 79% above Monday's close, suggesting the Street consensus sees substantial upside even after the recent rally. Bears counter that the company is loss-making across every reported multiple — PE, EV/EBITDA, and earnings yield are all deeply negative — and that the biologics revenue timeline remains uncertain. Cash burn trajectory is the real swing variable: it has improved materially over recent periods, but the gap between operational momentum and profitability is still wide enough to sustain the 16% short interest.
The ownership picture adds one notable wrinkle. MAK Capital One entered the register in Q1 2026 with a full 1.73 million-share initial position — nearly 5.8% of shares — suggesting at least one activist-leaning fund has taken a meaningful stake since the start of the year. That joins Vanguard adding 269,000 shares and State Street adding 145,000 in recent filings, pointing to broadening passive and institutional support at the same time short sellers are rebuilding. The March insider cluster — CEO Joseph Burnett sold roughly 43,000 shares at $11.53 alongside CFO and COO sales — was largely award-related, with each executive receiving roughly twice what they sold, net positive in share terms.
One data point from the most recent earnings history is worth noting descriptively: after the March 2026 print, the stock fell nearly 13% in a single session and extended the loss to roughly 15% over the following five days. The upcoming report is less a referendum on whether ClearPoint's platform is growing and more a test of whether the biologics segment can demonstrate the kind of repeatable, margin-accretive revenue that would justify a stock now trading at more than twice its level from earlier this year.
See the live data behind this article on ORTEX.
Open CLPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
